Literature DB >> 4006048

Blood and tissue concentrations of Bisantrene measured by a simple fluorometric assay.

M Buck, J S Kovach.   

Abstract

We have developed a simple sensitive fluorometric assay for the measurement of total Bisantrene in plasma, red blood cells, and tissues to facilitate preclinical and clinical pharmacologic assessment of this active anticancer agent. The assay was used to measure the plasma disappearance and tissue concentrations of Bisantrene in the rabbit. Results are comparable to those reported with HPLC assays and with measurement of radioactivity in combusted tissue following IV administration of radiolabeled Bisantrene. We demonstrated that when a plasma concentration of approximately 50 micrograms/ml is not exceeded, Bisantrene remains in solution at that concentration. If Bisantrene is introduced into plasma at a concentration exceeding 50 micrograms/ml, precipitation of the drug is initiated and continues until the plasma concentration is no greater than 15 micrograms/ml. This finding supports our previous recommendation that in clinical trials Bisantrene should be administered at low concentrations over prolonged periods of time to maximize the bioavailability of the drug by minimizing precipitation of the drug in plasma.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4006048     DOI: 10.1007/bf00257292

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  6 in total

1.  Tissue distribution and disposition of daunomycin (NCS-82151) in mice: fluorometric and isotopic methods.

Authors:  N R Bachur; A L Moore; J G Bernstein; A Liu
Journal:  Cancer Chemother Rep       Date:  1970-04

2.  Disposition and metabolic profile of a new antitumor agent: CL 216,942 (bisantrene) in laboratory animals.

Authors:  W H Wu; G Nicolau
Journal:  Cancer Treat Rep       Date:  1982-05

3.  Reversed-phase high-performance liquid chromatographic assay for the antineoplastic agent 9,10-anthracenedicarboxaldehyde bis(4,5-dihydro-1H-imidazol-2-yl hydrazone) dihydrochloride.

Authors:  G Powis
Journal:  J Chromatogr       Date:  1981-12-11

4.  High performance liquid chromatography of a new anticancer drug, ADCA--physicochemical properties and pharmacokinetics.

Authors:  Y M Peng; T P Davis; D S Alberts
Journal:  Life Sci       Date:  1981-07-27       Impact factor: 5.037

5.  Improved high-performance liquid chromatography of the new antineoplastic agents bisantrene and mitoxantrone.

Authors:  Y M Peng; D Ormberg; D S Alberts; T P Davis
Journal:  J Chromatogr       Date:  1982-12-10

6.  Disposition of bisantrene in humans and rabbits: evidence for intravascular deposition of drug as a cause of phlebitis.

Authors:  G Powis; J S Kovach
Journal:  Cancer Res       Date:  1983-02       Impact factor: 12.701

  6 in total
  1 in total

1.  Regional targeting of bisantrene by directed intravascular precipitation.

Authors:  J S Kovach; M Buck; T Tsukamoto; A Odegaard; M M Lieber
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.